{"id":7547,"date":"2013-06-12T02:54:19","date_gmt":"2013-06-12T06:54:19","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7547"},"modified":"2013-06-12T02:54:19","modified_gmt":"2013-06-12T06:54:19","slug":"vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547","title":{"rendered":"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#8217;s phase III results presented at 27th Annual Meeting"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/12\/2013 (wallstreetpr) &#8211;\u00a0The shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had surged by 24.98 percent to close at $12.56 per share for the end of last trading session on Tuesday. The shares of the company had been trading in the range of $10.25 to $12.77 per share during the day, thereby hitting new peaks. The shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had thus adjusted its 52 week high price to the new level of $12.77 per share, while the 52 week low price level of the company is at $2.92 per share.<\/p>\n<p style=\"text-align: justify;\">Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is primarily engaged in the development and commercialization of treatment therapies and drugs for the diseases related to central nervous system disorders. The principal product candidate of the company is Tasimelteon, which is to be used for the treatment of sleep and mood disorders with specific focus on Circadian Rhythm Disorders.<\/p>\n<p style=\"text-align: justify;\">The company had recently presented at the 27<sup>th<\/sup> Annual Meeting of Associated Sleep Societies held in Baltimore, SLEEP 2013, where Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had reported the results of Phase III studies of its drug candidate, Tasimelteon. The results had been reported to be successful in treating the Circadian Rhythm Disorders in visually challenged patients who find it difficult to adjust their biological clock to the normal day and night schedules.<\/p>\n<p style=\"text-align: justify;\">The success of the Phase III studies conducted by Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was measured in terms of sleep duration, nap duration and timing of sleep of the patients and the results were observed to be highly significant. The presentation of such successful results at the conference had caused the shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to surge to new peaks at heavy trading volumes.<\/p>\n<p style=\"text-align: justify;\">The company had witnessed the trade of 5.02 million shares on Tuesday, while the average trading volume of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is at 939,042 shares per day.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/12\/2013 (wallstreetpr) &#8211;\u00a0The shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had surged by 24.98 percent to close at $12.56 per share for the end [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":7548,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2140,2139],"stock_ticker":[],"class_list":["post-7547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqvnda","tag-vanda-pharmaceuticals-inc-nasdaqvnda","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#039;s phase III results presented at 27th Annual Meeting - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#039;s phase III results presented at 27th Annual Meeting - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/12\/2013 (wallstreetpr) &#8211;\u00a0The shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had surged by 24.98 percent to close at $12.56 per share for the end [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-12T06:54:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#8217;s phase III results presented at 27th Annual Meeting\",\"datePublished\":\"2013-06-12T06:54:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg\",\"keywords\":[\"NASDAQ:VNDA\",\"Vanda Pharmaceuticals Inc (NASDAQ:VNDA)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\",\"name\":\"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s phase III results presented at 27th Annual Meeting - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg\",\"datePublished\":\"2013-06-12T06:54:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#8217;s phase III results presented at 27th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s phase III results presented at 27th Annual Meeting - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547","og_locale":"en_US","og_type":"article","og_title":"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s phase III results presented at 27th Annual Meeting - Wall Street PR","og_description":"Boston, MA 06\/12\/2013 (wallstreetpr) &#8211;\u00a0The shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) had surged by 24.98 percent to close at $12.56 per share for the end [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-12T06:54:19+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#8217;s phase III results presented at 27th Annual Meeting","datePublished":"2013-06-12T06:54:19+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg","keywords":["NASDAQ:VNDA","Vanda Pharmaceuticals Inc (NASDAQ:VNDA)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547","url":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547","name":"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s phase III results presented at 27th Annual Meeting - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg","datePublished":"2013-06-12T06:54:19+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-1-drug-giants-alamy.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vanda-pharmaceuticals-inc-nasdaqvndas-phase-iii-results-presented-at-27th-annual-meeting-7547#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)&#8217;s phase III results presented at 27th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7547"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7548"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7547"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}